SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+3.52%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$842M
AUM Growth
+$842M
(-17%)
Cap. Flow
-$185M
Cap. Flow
% of AUM
-22.02%
Top 10 Holdings %
Top 10 Hldgs %
43.02%
Holding
132
New
22
Increased
18
Reduced
31
Closed
44
Top Buys
| 1 |
Merck
MRK
|
$26.6M |
| 2 |
Amazon
AMZN
|
$13.5M |
| 3 |
Burlington
BURL
|
$12.1M |
| 4 |
Sanofi
SNY
|
$12M |
| 5 |
FIVE9
FIVN
|
$11.7M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$52.2M |
| 2 |
Pfizer
PFE
|
$51.8M |
| 3 |
AbbVie
ABBV
|
$17.9M |
| 4 |
Johnson & Johnson
JNJ
|
$14.3M |
| 5 |
AstraZeneca
AZN
|
$13.8M |
Sector Composition
| 1 | Healthcare | 74.17% |
| 2 | Technology | 9.76% |
| 3 | Consumer Discretionary | 5.09% |
| 4 | Communication Services | 3.02% |
| 5 | Industrials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $62.9M | 6.91% | 464,194 -132,100 | -22% | -$17.9M |
|
|
2
AstraZeneca
AZN
$248B
| $61.5M | 6.76% | 1,055,467 -236,200 | -18% | -$13.8M |
|
|
3
Sanofi
SNY
$121B
| $54.3M | 5.97% | 1,083,400 +240,000 | +28% | +$12M |
|
|
4
Eli Lilly
LLY
$657B
| $44.1M | 4.85% | 159,695 -188,800 | -54% | -$52.2M |
|
|
5
Merck
MRK
$210B
| $26.6M | 2.92% | +346,423 | New | +$26.6M |
|
|
6
Johnson & Johnson
JNJ
$427B
| $26.5M | 2.92% | 155,123 -83,825 | -35% | -$14.3M |
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $25.8M | 2.83% | 1,176,585 +425,982 | +57% | +$9.32M |
|
|
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
| $21.2M | 2.33% | 342,566 +94,649 | +38% | +$5.87M |
|
9
Kymera Therapeutics
KYMR
$2.95B
| $20.2M | 2.22% | 318,667 -40,593 | -11% | -$2.58M |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $19.2M | 2.11% | 216,977 +67,960 | +46% | +$6M |
|
11
Microsoft
MSFT
$3.77T
| $17M | 1.87% | 50,536 -17,000 | -25% | -$5.72M |
|
12
Generac Holdings
GNRC
$10.9B
| $14.8M | 1.63% | 42,057 -28,956 | -41% | -$10.2M |
|
|
13
Amazon
AMZN
$2.44T
| $14M | 1.54% | 4,200 +4,039 | +2,509% | +$13.5M |
|
14
Meta Platforms (Facebook)
META
$1.86T
| $14M | 1.54% | 41,622 +7,222 | +21% | +$2.43M |
|
|
15
Pfizer
PFE
$141B
| $13.5M | 1.48% | 228,528 -878,000 | -79% | -$51.8M |
|
16
Palo Alto Networks
PANW
$127B
| $13.4M | 1.47% | 24,000 -7,000 | -23% | -$3.9M |
|
17
C4 Therapeutics
CCCC
$185M
| $12.8M | 1.41% | 398,469 +16,695 | +4% | +$538K |
|
|
18
Burlington
BURL
$18.3B
| $12.1M | 1.33% | +41,501 | New | +$12.1M |
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| $12M | 1.32% | 423,248 -125,395 | -23% | -$3.56M |
|
|
20
FIVE9
FIVN
$2.08B
| $11.7M | 1.29% | +85,556 | New | +$11.7M |
|
21
Kura Oncology
KURA
$686M
| $11.7M | 1.28% | 832,238 +43,503 | +6% | +$609K |
|
22
Altimmune
ALT
$338M
| $11.4M | 1.25% | 1,244,241 +155,387 | +14% | +$1.42M |
|
23
Fate Therapeutics
FATE
$120M
| $10.9M | 1.19% | 185,476 -33,823 | -15% | -$1.98M |
|
24
Merus
MRUS
$4.98B
| $10.8M | 1.19% | 340,951 +31,524 | +10% | +$1M |
|
25
Relmada Therapeutics
RLMD
$37.2M
| $10.8M | 1.18% | +478,208 | New | +$10.8M |
|